In 2024, the overall reporting rate for special materials with out-of-pocket co-payments under National Health Insurance (NHI) was 0.0569%.1
In that same year, coronary drug-eluting stents accounted for 73.1%, while intramedullary nail sets with special functions and materials accounted for 79.3%.1
While the overall figure is less than one-tenth of one percent, individual items exceed 70%. This article addresses this discrepancy.
Zero Point Zero Five Six Nine Percent
Let's start with the macro numbers. The calculation for the reporting rate of special materials with out-of-pocket co-payments is: the number of reports for such materials divided by the total number of reports for all special materials.1
The rates were 0.0523% in 2022, 0.0551% in 2023, and 0.0569% in 2024—a slight upward trend over three years, averaging approximately 0.0547%.1
This number is so small it is easily overlooked. However, the denominator includes all special materials, including those under full coverage; to see the real situation, one must look at specific categories.
Two Categories Exceeding 70%
The NHI splits special materials with out-of-pocket co-payments into ten major categories, each using a different calculation: the numerator is the volume of co-payment reports for the same use, and the denominator is the sum of co-payment reports plus full-coverage reports for that same use.1
In 2024, the highest proportion was intramedullary nail sets at 79.3%, followed by coronary drug-eluting stents at 73.1%.1
The remaining categories in descending order are: special function intraocular lenses (49.2%), special function pacemakers (49.1%), special function catheters for treating complex arrhythmia (46.9%), drug-eluting devices for treating superficial femoral artery stenosis (46.2%), special material biological tissue heart valves (43.2%), special material artificial hip joints (31.3%), cerebrospinal fluid shunt systems (9.2%), and prosthetics (4.1%).1
Source: NHI Committee "2024 National Health Insurance Supervisory Indicator Monitoring Results Report," Indicator 4.3
Analysis by the National Health Insurance Committee (NHIC) indicates that the reporting rates for coronary drug-eluting stents and intramedullary nail sets have exceeded 70%, meaning they are "approaching routine use." The NHIC has repeatedly requested the National Health Insurance Administration (NHIA) to evaluate including them in full coverage.1
Four Rising, One Falling
Over the last three years, four major categories have seen their proportions rise annually: intraocular lenses, coronary drug-eluting stents, drug-eluting devices for treating superficial femoral artery stenosis, and intramedullary nail sets.1
One category has seen a significant decline: cerebrospinal fluid shunt systems dropped from 70.5% in 2022 to 12.0% in 2023, and 9.2% in 2024.1
The remaining five categories are largely stable or fluctuating; for example, arrhythmia catheters rose from 53.0% to 59.0% before dropping back to 46.9%.1
| 2022 | 70.5 | Included in coverage starting Nov 1 of that year |
|---|---|---|
| 2023 | 12 | |
| 2024 | 9.2 |
Source: NHIC "2024 National Health Insurance Supervisory Indicator Monitoring Results Report," Indicator 4.3
That One Time Full Coverage Was Implemented
The turning point for cerebrospinal fluid shunt systems has a specific date. Starting November 1, 2022, the NHIA included two high-market-share sub-functional categories of these materials into full NHI coverage.1
NHIC analysis shows that after being included in full coverage, the reporting rate showed a downward trend year by year. From 70.5% to 9.2%, a drop of over 60 percentage points.1
The significance of this case is not to prove that "full coverage causes a drop," but to demonstrate how the system works: when the usage rate of a certain category of special materials with co-payments remains high for a long time, the NHIC will request a review. After evaluation by the NHIA, it can be moved into full coverage, and that "co-payment" slot disappears.
The NHIC Threshold
The NHIC has established a principle: if the usage proportion of special materials with co-payments increases annually and exceeds 50%, an evaluation should be initiated—balancing citizens' medical needs with NHI financial stability—to include highly demanded, urgent, or essential materials in full coverage.1
Looking back at 2024 through this lens, only intramedullary nail sets (79.3%) and coronary drug-eluting stents (73.1%) crossed the 50% threshold; intraocular lenses (49.2%) and special function pacemakers (49.1%) are close to the threshold.1
The progress of the NHIA's handling varies. Coronary drug-eluting stents are moving toward "bundled payment for clinical items," prioritizing full coverage for patients with ST-segment elevation myocardial infarction (STEMI). For intramedullary nail sets, the NHIA has requested a Health Technology Assessment (HTA) from the Taiwan Food and Drug Administration's Center for Drug Evaluation. The commission is expected in March 2025, with the report completed by July. The estimated cost of transitioning to full coverage is approximately NT$450 million (calculated based on 2023 reporting volumes).1
How to Read This Table
This table is most easily misread in two ways.
The first is to look only at the overall 0.0569% and conclude that "the co-payment issue is not a big deal." This number is correct, but it averages out the massive differences between the ten major categories.
The second is to look only at 79.3% and conclude that "NHI is making citizens pay for everything themselves." This number is also correct, but it only represents the intramedullary nail category, and this ratio is determined by its definition: the denominator only counts co-payment and full-coverage reports for the same use. A high proportion means the volume of full-coverage items is relatively low.1
A more accurate reading is: a co-payment is an "option" slot. For most special materials, this slot is very small; for a few high-priced materials, this slot is very large. The system design ensures that this slot moves according to coverage policies—the cerebrospinal fluid shunt system is an example of a slot that was moved.
The next time the NHIC publishes this table, two things are worth watching: whether intramedullary nail sets and coronary drug-eluting stents will follow the path of cerebrospinal fluid shunt systems, and whether those four rising categories will push the overall proportion above 0.0569%.
Further Reading:
- Average Life Expectancy in Taiwan — Medical benefits and demographic structure are two sides of the same coin
- Emergency Room Congestion — How coverage and resource allocation reflect in patient flow
- Taiwanese Healthcare and National Health Insurance — The upstream of global budgets, co-payments, and benefit decisions
References
- 2024 National Health Insurance Supervisory Indicator Monitoring Results Report (National Health Insurance Committee, Ministry of Health and Welfare, November 2025) — Indicator 4.3 specifies the overall reporting rates for special materials with co-payments from 2022–2024 (0.0523%, 0.0551%, 0.0569%) and the proportions of the 10 major categories (intramedullary nail sets 76.5%, 77.9%, 79.3%; coronary drug-eluting stents 70.2%, 72.3%, 73.1%; intraocular lenses 44.5%, 47.2%, 49.2%, etc.), as well as the drop in cerebrospinal fluid shunt systems from 70.5% to 9.2% after inclusion in full coverage on November 1, 2022; the NHIC 50% threshold principle; and the NT$450 million financial estimate and HTA timeline for intramedullary nail sets.↩234567891011121314151617